Lilly to acquire Disarm Therapeutics

THe FINANCIAL — Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration. Disarm has discovered novel, potent SARM1 inhibitors and is advancing…

3 mins read